npm1 - Robuta Search

https://www.mdanderson.org/newsroom/targeting-menin-induces-responses-in-acute-leukemias-with-kmt2a.h00-159545268.html Targeting menin induces responses in acute leukemias with KMT2A rearrangements or NPM1 mutations |... Researchers from The University of Texas MD Anderson Cancer Center showed that inhibiting menin with revumenib, previously known as SNDX-5613, yielded... https://www.dana-farber.org/newsroom/news-releases/2025/fda-approves-menin-inhibitor-for-patients-with-acute-leukemia-with-npm1-mutation-backed-by-dana-farber-science FDA approves menin inhibitor for patients with acute leukemia with NPM1 mutation, backed by... The U.S. Food and Drug Administration (FDA) approved revumenib, a first-in-class oral menin inhibitor, for the treatment of adults and children one year and... https://www.mdanderson.org/research/research-resources/core-facilities/molecular-diagnostics-lab/services/MD-NPM1-MRD-Mutation-Analysis.html MD NPM1 MRD Mutation Analysis (NGS) | UT MD Anderson mutation analysis md npm1 mrd ngs https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-revumenib-relapsed-or-refractory-acute-myeloid-leukemia-susceptible-npm1-mutation? FDA approves revumenib for relapsed or refractory acute myeloid leukemia with a susceptible NPM1... On October 24, 2025, the Food and Drug Administration approved revumenib (Revuforj, Syndax Pharmaceuticals, Inc.), a menin inhibitor, for relapsed or... https://www.thermofisher.com/antibody/product/Phospho-NPM1-Thr199-Antibody-Recombinant-Monoclonal/RAB01780 Phospho-NPM1 (Thr199) Recombinant Rabbit Monoclonal Antibody | Invitrogen (RAB01780) Detect Phospho-NPM1 (Thr199) in WB, IHC (P), ELISA, ICC/IF, IP. Reacts with Rabbit. Catalog # RAB01780 rabbit monoclonal phospho npm1 recombinant antibody https://www.mdpi.com/2072-6694/16/20/3443 Immunotherapeutic Potential of Mutated NPM1 for the Treatment of Acute Myeloid Leukemia Acute myeloid leukemia (AML) is a malignant disease of the blood and bone marrow that is characterized by uncontrolled clonal proliferation of abnormal myeloid... for the immunotherapeutic potential mutated npm1 https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2024-04789&r=1 Revumenib with Cytarabine, Daunorubicin and Midostaurin for the Treatment of Patients with NPM1 and... Revumenib with Cytarabine, Daunorubicin and Midostaurin for the Treatment of Patients with NPM1 and FLT3 Mutated Acute Myeloid Leukemia cytarabine daunorubicin https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2019-07963&r=1 A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1... A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation